CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of CEL-SCI (NYSE:CVM) in a research note published on Sunday. The brokerage issued a sell rating on the stock.

CEL-SCI Price Performance

Shares of CVM stock opened at $0.22 on Friday. CEL-SCI has a twelve month low of $0.18 and a twelve month high of $2.39. The company has a market capitalization of $17.31 million, a PE ratio of -0.45 and a beta of 0.95. The company has a current ratio of 1.07, a quick ratio of 1.09 and a debt-to-equity ratio of 0.66. The firm has a fifty day simple moving average of $0.34 and a 200-day simple moving average of $0.59.

Institutional Inflows and Outflows

An institutional investor recently raised its position in CEL-SCI stock. Geode Capital Management LLC raised its holdings in CEL-SCI Co. (NYSE:CVM) by 9.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 612,861 shares of the company’s stock after purchasing an additional 53,879 shares during the period. Geode Capital Management LLC owned about 0.96% of CEL-SCI worth $650,000 as of its most recent SEC filing. Institutional investors own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.